Madhu Kumar
Stock Analyst at Goldman Sachs
(2.93)
# 1,674
Out of 5,090 analysts
145
Total ratings
56.44%
Success rate
23.95%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $169.56 | +9.11% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $8.93 | -32.81% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $9.59 | +77.36% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.23 | +226.53% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $233.58 | -33.64% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $65.67 | -19.29% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $9.83 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $61.44 | +18.82% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $23.65 | +496.32% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $20.38 | +66.83% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.20 | +173.35% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $7.13 | +96.35% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.88 | +93.10% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $23.58 | -78.80% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.42 | +230.58% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $12.79 | +595.86% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $9.28 | +1,193.10% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.22 | +4,516.81% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $9.61 | +784.50% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $4.74 | +722.78% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $21.33 | +167.23% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.43 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.06 | +84,805.66% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $6.50 | +207.69% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.34 | +29,398.53% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $45.04 | -22.29% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $17.74 | +125.48% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $35.37 | +1,325.14% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $458.55 | -49.84% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $13.07 | +8,507.50% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.06 | +3,673.58% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $30.79 | -30.17% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $56.88 | -58.68% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $169.56
Upside: +9.11%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $8.93
Upside: -32.81%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $9.59
Upside: +77.36%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.23
Upside: +226.53%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $233.58
Upside: -33.64%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $65.67
Upside: -19.29%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $9.83
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $61.44
Upside: +18.82%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $23.65
Upside: +496.32%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $20.38
Upside: +66.83%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.20
Upside: +173.35%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $7.13
Upside: +96.35%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.88
Upside: +93.10%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $23.58
Upside: -78.80%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.42
Upside: +230.58%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $12.79
Upside: +595.86%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $9.28
Upside: +1,193.10%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.22
Upside: +4,516.81%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $9.61
Upside: +784.50%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $4.74
Upside: +722.78%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $21.33
Upside: +167.23%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.43
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.06
Upside: +84,805.66%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $6.50
Upside: +207.69%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.34
Upside: +29,398.53%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $45.04
Upside: -22.29%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $17.74
Upside: +125.48%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $35.37
Upside: +1,325.14%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $458.55
Upside: -49.84%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $13.07
Upside: +8,507.50%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.06
Upside: +3,673.58%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $30.79
Upside: -30.17%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $56.88
Upside: -58.68%